



## **Roche Position on Biotechnology – Safety, Health and Environmental Aspects**

### **Roche's Position**

Roche views biotechnology as a technology that opens up opportunities for developing innovative new therapies of high quality for unmet medical needs. Roche is therefore convinced that biotechnology must be further fostered. In addition, biotechnology has the potential to replace certain chemical processes and thereby can make production more ecologically friendly and thus more sustainable. Roche actively explores such opportunities.

The significance of biotechnology as a core application in the Roche Group has increased tremendously. Many of Roche's top selling products are being produced by harnessing biotechnology.

At the same time, Roche is fully aware of the risks involved in developing new products and technologies and of the need to be cautious when utilizing them. Roche is therefore carefully monitoring all biotechnological products and processes with regard to both their therapeutic use and their potential impact on workers and the environment. Roche is convinced that this care must be exercised not only in the production and use of innovator/originator products but also for so-called biosimilars or follow-on biologics ('Roche Position on Similar Biotherapeutic Products - Biosimilars')

[https://www.roche.com/dam/jcr:d24f94c9-90c1-4d17-b6df-e43b07c21ef3/en/roche\\_position\\_biosimilars.pdf](https://www.roche.com/dam/jcr:d24f94c9-90c1-4d17-b6df-e43b07c21ef3/en/roche_position_biosimilars.pdf) )

Roche is committed to handling SHE matters with the same sense of responsibility, and just as methodically, as issues of quality, productivity and cost-efficiency ([https://www.roche.com/dam/jcr:26cdac00-cbcd-462d-97c1-df87b2ceaa9b/en/she\\_policy.pdf](https://www.roche.com/dam/jcr:26cdac00-cbcd-462d-97c1-df87b2ceaa9b/en/she_policy.pdf)).

### **The Global Situation**

Biotechnology, in particular in conjunction with the use of genetically modified organisms, is a topic that has led to considerable debate in many countries. The controversy most frequently centers on "green biotechnology", i.e. the use of biotechnology in the production of food and feed. "Red biotechnology", in contrast, i.e. biotechnological applications in the medical field, including processes enabled by genetically modified organisms, enjoys a more positive image as it has proven indispensable for the production of medicines and vaccines that have brought great progress in the prevention and treatment of medical conditions.



The special importance of biotechnological processes in the production of pharmaceuticals can be ascribed to the following three advantages:

- Biotechnological processes are capable of producing molecules so complex that it would be very difficult or even impossible to synthesize them chemically.
- Biotechnological processes allow the synthesis of molecules in a single process step that would require several steps if conventional chemical synthesis were chosen.
- Biotechnological processes can be safer and more ecologically friendly than comparable chemical processes.

### **The Situation at Roche: Safety**

For the commercial production of pharmaceuticals, Roche's biotechnological processes use micro organisms or cell lines exclusively from the lowest possible risk group, which includes only agents that, by definition, "present no or a low individual and community risk". They are not pathogenic to humans and animals and have no adverse environmental impact.

In research and development, and in certain processes used for the commercial manufacture of diagnostic tests, micro organisms may be used that can cause disease. In handling these agents, Roche strictly complies with the appropriate biosafety standards recognized across the world. Genetically modified micro organisms and cells are generally classified in the same risk group as their naturally occurring variants, although they are often dependent on a protected environment and will die when released. Roche complies with all pertinent regulations and additionally performs individual process risk assessments based on the precautionary principle.

Unlike most classical chemical processes, biotechnological transformation ("upstream") processes take place in an aqueous environment. This eliminates the risk of fire or explosion associated with certain solvents frequently used in chemical syntheses. The use of toxic chemicals in biotechnological process steps is limited, as such chemicals could easily have an adverse effect on the cells involved. However, organic solvents still play a role in some "downstream" biotechnological processes, where they are used to extract certain products from the fermentation broth and to purify them.

### **The Situation at Roche: Health**

Small amounts of biotechnological products may be taken up by the worker during occupational handling. Enzymes, a typical class of biotechnological products, are potent allergens, and there are numerous reports of work-related allergies, in particular from the food, feed, paper and detergent industries. Concerns about the potential of other biotechnological products used in medical



treatment to cause work-related allergies have so far not proven justified. But vigilance is both needed and applied.

“Upstream” production processes must be strictly protected from outside contamination. This protection must also be guaranteed “downstream” because many of the biotechnologically manufactured drugs are peptides or proteins, which are typically administered by injection and must therefore be protected during manufacture. Such operational necessities help prevent exposure of workers to these processes and their products.

Health surveillance is important to ensure that no adverse health effects occur in the workers or that they are detected early if they do. Evaluation of these surveillance data has shown that the protective measures taken at the workplace are effective.

One of the most sophisticated groups of commonly used biotechnological medicines is monoclonal antibodies (MAbs). MAbs are very effective drugs, as they are designed and developed to target the diseased organ directly and exclusively. For this reason, often no effects of the drug are expected in healthy individuals. Side effects in patients are generally mild and predictable. However, there are examples indicating that serious unexpected effects can occur due to MAb administration. Therefore, Roche handles this class of drugs with all necessary safety measures, as appropriate to any Roche product. New classes of biotechnological medicines such as Antibody-Drug-Conjugates, fusion proteins and bi-specific MAbs require special measures to protect workers and the environment.

### **The Situation at Roche: Environmental Protection**

Where very complex and large molecules must be synthesized, there is often no alternative to biotechnology. These processes are known to consume significant amounts of energy, e.g. for handling the large volumes of water. Efforts are therefore made to reduce energy consumption and water use. Mindful of this, Roche has established an ongoing programme to reduce energy consumption with clear targets. New biotechnological installations are already more than 50% more energy-efficient than the older ones.

Patients treated with any of Roche’s biotechnological products metabolise them and generally do not excrete them into the environment. Product residues from manufacturing processes are easily biodegradable overall and give no rise to environmental concerns. The use of detergents is necessary to ensure cleanliness and control of the microbiological conditions of the production equipment. The environmental no-effect concentrations of some of these detergents or their degradation products are low, and Roche is working to the most conservative emission standards.

In summary, the biotechnological processes performed somewhat better with regard to the consumption of raw materials, water, energy and waste, as well as to other process emissions. The main ecological advantage lies in the nature of the raw materials and the solid waste. Whilst the



consumption of raw materials and production of solid waste in the chemical processes is actually lower, the overwhelming majority of the raw materials in the biotechnological process come from renewable sources and most of the waste is biomass that can be composted or is otherwise biodegradable. The treatment of waste streams is optimised for each process, ensuring state-of-the-art biological safety but at the same time avoiding an overall negative environmental impact due to unnecessary energy consumption.

### **Further information**

The topic of biotechnology has been addressed a number of times in the annual Roche Group Reports on safety and environmental protection and sustainability reports:

[https://www.roche.com/sustainability/what we do/for communities and environment/environment/our she goals and performance.htm](https://www.roche.com/sustainability/what_we_do/for_communities_and_environment/environment/our_she_goals_and_performance.htm)

and <http://www.gene.com/good/sustainability>.

Roche has also published various documents on biotechnology, e.g. a booklet entitled “Biotechnology – new directions in medicine”

[http://www.roche.com/biotechnology\\_new\\_directions\\_in\\_medicine.pdf](http://www.roche.com/biotechnology_new_directions_in_medicine.pdf)

### **Contacts**

Peter Schnurrenberger, Chief SHE Officer, [peter.schnurrenberger@roche.com](mailto:peter.schnurrenberger@roche.com),  
+41 61 68 85213, Basel.

David Miedinger, Deputy Chief Occupational Health Officer, [david.miedinger@roche.com](mailto:david.miedinger@roche.com),  
+41 61 68 71989, Basel.

*This position paper was updated and approved by the Corporate Sustainability Committee on April 28, 2011. It was reviewed in April 2020.*